Browsing by Project


Or, select a letter below to browse by title
0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Results 7572 to 7591 of 10536 previous   next
TitleP-Investigator
S. Li was supported by the U.S. Department of Energy under contract DE–AC02–76SF00515, and P. Lowdon by the Agence Na-tionale de la Recherche under project No. ANR–18–ERC1–0002. P.J. Silva acknowledges support from FCT under the contracts SFRH/BPD/40998/2007 and SFRH/BPD/109971/2015, and both O. Oliveira and P.J. Silva acknowledge support from FCT under the contracts UID/FIS/04564/2016 and CERN/FIS-COM/0029/2017. This work was granted access to the HPC resources of the PDC Cen-ter for High Performance Computing at the KTH Royal Institute of Technology, Sweden, made available within the Distributed Eu-ropean Computing Initiative by the PRACE-2IP, receiving fund-ing from the European Community’s Seventh Framework Pro-gramme (FP7/2007-2013) under grand agreement no. RI-283493. The use of Lindgren has been provided under DECI-9 project COIM-BRALATT. We acknowledge that the results of this research have been achieved using the PRACE-3IP project (FP7 RI312763) re-source Sisu based in Finland at CSC. The use of Sisu has been provided under DECI-12 project COIMBRALATT2. We also acknowl-edge the Laboratory for Advanced Computing at the University of Coimbra (http://www.uc .pt /lca) for providing access to the HPC re-source Navigator.
S.A. Papiris reports grants, personal fees and nonfinancial support from La Roche Hoffman and Boehringer Ingelheim, and other support from Savara, outside the submitted work. F. Bonella reports grants and personal fees from Savara Pharma outside the submitted work. R. Borie has received consulting fees from Boehringer Ingelheim, Roche and Sanofi, outside the submitted work; payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from Boehringer Ingelheim and Roche, outside the submitted work; support for attending meetings and/or travel received from Boehringer Ingelheim, Roche and Chiesi outside the submitted work; and participation on a data safety monitoring or advisory board for Savara, outside the submitted work. M. Molina-Molina reports personal fees and grants from Esteve-Teijin, Roche and Boehringer Ingelheim, outside the submitted work. E. Jouneau reports personal fees and other support from Actelion, AIRB, AstraZeneca, Bellerophon Therapeutics, Biogen, BMS, Boehringer Ingelheim, Chiesi, FibroGen, Galecto Biotech, Genzyme, Gilead, GlaxoSmithKline, LVL, Mundipharma, Novartis, Pharm-Olam, Pfizer, Pliant Therapeutics, F. Hoffmann-La Roche, Ltd, Sanofi and Savara-Serendex, outside the submitted work. C. McCarthy is a scientific advisory board member of Savara Inc. unrelated to this work and has not received any payment from Savara Inc. for any work to date. E. Bendstrup reports grants and personal fees from Boehringer Ingelheim and Hofmann la Roche, and personal fees from Galapagos, outside the submitted work. M. Griese has received grants or contracts from Boehringer Ingelheim, outside the submitted work; has participated on a data safety or advisory board for Boehringer Ingelheim, outside the submitted work; and is the Head of chILD-EU, outside the submitted work. E.D. Manali reports personal fees and nonfinancial support from La Roche Hoffman; grants, personal fees and nonfinancial support from Boehringer Ingelheim; and other support from Savara, all outside the submitted work. The remaining authors have nothing to disclose.
S.S. has received grants from the NIH (HL124187, HL140469, HL148786 and NYSTEM C32562GG) and Transatlantic Foundation Leducq
S.Z., Y.W., W.X. are supported by the China Scholarship Council. G.K. is supported by the Ligue contre le Cancer (équipes labelisées); Agence National de la Recherche (ANR)— Projets blancs; ANR under the frame of E-Rare-2, the ERA-Net for Research on Rare Diseases; Association pour la recherche sur le cancer (ARC); Cancéropôle Ile-de- France; Institut National du Cancer (INCa); Fondation Bettencourt-Schueller; Fondation de France; Fondation pour la Recherche Médicale (FRM); the European Commission (ArtForce); the LabEx Immuno-Oncology; the SIRIC Stratified Oncology Cell DNA Repair and Tumor Immune Elimination (SOCRATE); and the SIRIC Cancer Research and Personalized Medicine (CARPEM). P.A.G. is supported by the Australian Research Council (DP180100612).
saberportugues.pt
SAF2017-87538-R (to RT) from the Ministry of Economy and Competitiveness of Spain
SafeFire PCIF/SSO/0163/2019
SafeForest CENTRO-01-0247-FEDER-045931
SAICT 000006 SUSpENsE
SAICT project nº 31296, “COMP4UAVs”, supported by POCI in its FEDER component and by FCT-IP
SAICT-45-2017-02
SAICT/30935/2017
SAICT/Processos de Atribuição de Slots em Aeroportos: Desenvolvimentos nas Orientações e Práticas Atuais
SAICTPAC/0004/2015-POCI-01-0145-FEDER-016434
SAICTPAC/0010/2015
SAICTPAC/0019/ 2015-LISBOA- 01-0145-FEDER-016405
SAICTPAC/0032/2015
SAICTPAC/0040/2015
SAICTPAC/0046/2015
SAICTPAC/0046/2015 - POCI-01-0145-FEDER-016387
Results 7572 to 7591 of 10536 previous   next